Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity
Session Type: Abstract Submissions (ACR)
New biomarkers for monitoring Rheumatoid Arthritis (RA) disease activity and prognosis of progression are urgently needed to individually optimize drug therapy and prevent joint destruction. Serum Matrix Metalloproteinase 3 (MMP-3) has been proposed to be such a marker. Thus we set out to correlate MMP-3 serum levels in Rheumatoid Arthritis patients with their individual disease activity.
64 sera from adult patients (44 female, 20 male) with established RA and 97 control sera from adult healthy donors (48 female, 49 male) were analyzed using the AESKULISA DF MMP-3 kit. The 64 RA patients were classified as “Active” or “Inactive” according to their individual disease activity based on clinical data. Both RA groups were correlated to their individual MMP-3 serum concentrations (termed as “elevated” and “non-elevated” MMP-3 levels). The normal range of MMP-3 concentration in serum was determined by calculating the 95th percentile of the measured MMP-3 concentrations for each gender.
Of the 64 RA patients, 35 were classified as “Active” and 29 as “Inactive” based on their individual disease activity. Normal MMP-3 serum concentrations were determined as: up to 60 ng/ml and up to 120 ng/ml for females and males, respectively. 89% (31/35) of “Active” patients had elevated and only 11% (4/35) had normal or borderline MMP-3 levels. 90% (26/29) of “Inactive” patients had normal and only 10% (3/29) had elevated MMP-3 levels.
Serum concentration of MMP-3 exhibits a high correlation with RA disease activity.
« Back to 2012 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/matrix-metalloproteinase-3-a-biomarker-of-disease-activity-in-rheumatoid-arthritis/